Quantification of Human Papillomavirus cell-free DNA from low volume blood plasma samples by digital PCR

Fabian Rosing[1], Matthias Meier[2], Lea Schroeder[1], Simon Laban[2], Thomas Hoffmann[2], Andreas Kaufmann[3], Oliver Siefer[4], Nora Würdemann[4], Jens Peter Klußmann[4], Thorsten Rieckmann[5, 6], Yvonne Alt[1], Daniel Faden [7, 8, 9], Tim Waterboer[1] and Daniela Höfler[1]

[1] Infections and Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
[2] Department of Otorhinolaryngology and Head & Neck Surgery, Head and Neck Cancer Center of the Comprehensive Cancer Center Ulm, University Medical Center Ulm, Ulm, Germany.
[3] Department of Gynecology, HPV Research Laboratory, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
[4] Department of Otorhinolaryngology, Head and Neck Surgery, Medical Faculty, University of Cologne, Cologne, Germany.
[5] Department of Radiobiology & Radiation Oncology, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20246 Hamburg, Germany
[6] Department of Otolaryngology and Head and Neck Surgery, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
[7] Department of Otolaryngology-Head and Neck Surgery, Boston Medical Center, Boston, Massachusetts.
[8] Department of Otolaryngology-Head and Neck Surgery, Harvard Medical School, Boston, Massachusetts.
[9] Mass Eye and Ear, Boston, Massachusetts.

Abstract

The incidence rate of human papillomavirus-driven oropharyngeal cancer (HPV-OPC) is increasing in many countries with high human development index. HPV cell-free DNA (cfDNA) isolated from relatively large amounts of blood plasma (typically 3-4 ml) has been successfully used for therapy surveillance of HPV-OPC patients. A currently highly discussed application of HPV-cfDNA is early detection of HPV-OPC in symptom-free individuals. This requires particularly sensitive and specific cfDNA detection methods as viral copy numbers can be very low. To study the predictive power of pre-diagnostic HPV-cfDNA, archived samples from epidemiological cohorts with limited plasma volume are an important source.

To establish a cfDNA detection workflow optimized for low plasma volumes we compared two cfDNA purification methods (MagNA Pure 96 and QIAamp ccfDNA/RNA) and two digital PCR systems (Biorad QX200 and QIAGEN QIAcuity One). Final assay validation included 65 low volume plasma samples from OPC patients with defined HPV status (34 HPV16+, 1 HPV33+, 2 HPV58+, 28 HPV-negative) stored for 2-9 years.

MagNA Pure 96 yielded a 28% higher cfDNA isolation efficiency in comparison to the QIAamp ccfDNA/RNA kit. Both digital PCR systems showed comparable analytic sensitivity (limit of detection 6-17 copies for both HPV16 and HPV33), but the higher multiplexing capacity allowed the QIAcuity to detect both HPV types in the same assay. In the validation set, the assay had a sensitivity of 80% (n=28/35) for detecting HPV16 and HPV33, and a specificity of 97% (n=29/30). In samples with ≥750 μl plasma available, the sensitivity was 85% (n=17/20), while in samples with <750 μl plasma the sensitivity was 73% (n=11/15).

Despite the expected drop in sensitivity with decreased plasma volume, the assay is sensitive and highly specific even in low volume samples, and thus suited for studies exploring HPV-cfDNA as an early HPV-OPC detection marker in low volume archival material.

Keywords

HPV, liquid biopsy, digital PCR, OPC, cfDNA, early detection

1. Introduction

Infection with high-risk human papillomavirus (HPV) is one of the leading causes of cancer worldwide, accounting for 5 % of all cases [1]. HPV is a sexually transmitted infection and is primarily associated with cancers of ano-genital sites, such as vulvar, penile, and anal carcinomas, and particularly with more than 99% of all cervical carcinoma cases [1], but also head and neck cancer, such as oropharyngeal cancer (OPC) [2]. Due to a strong increase of HPV-driven OPC, OPC is now the most frequent HPV-driven cancer in some countries with high human development index, especially in North America and Western Europe [2]. HPV-driven OPC mostly arises from the epithelium of the tonsillar crypts and the base of tongue and is often diagnosed after regional spread to nearby lymph nodes, making extensive treatment necessary [3]. The clinical standard for determining the HPV status of OPC is p16-immunohistochemistry (p16-IHC) [4], often accompanied by HPV DNA detection methods, such as PCR. Despite the overall good prognosis of HPV-driven OPC, survivors often experience serious morbidity after treatment, including speech impediments and dysphagia [5]. Early detection of OPC may decrease the need for extensive treatment, possibly leading to an improved quality of life. This is complicated by the fact that, contrary to cervical carcinoma, no precancerous lesions of OPC are known to date [6]. Therefore, screening and early detection (i.e. secondary prevention) are currently not feasible. Primary prevention through HPV vaccination is highly effective at preventing cervical cancer and expectedly, HPV-driven OPC as well, as the vaccine reduces the prevalence of oral high-risk HPV infection [7]. However, due to OPC mainly affecting males, and the low vaccine uptake in males, HPV vaccination is not expected to have an impact on HPV-OPC incidence rate for decades to come. Hence, HPV-driven OPC incidence rates are projected to keep increasing until at least the mid-2030s [8].

One biomarker that has recently gained a lot of attention in management of OPC is HPV cell-free DNA (cfDNA) from blood plasma. Cells that undergo apoptosis or necrosis shed DNA into their environment, and subsequently also the blood stream [9]. In healthy individuals, plasma-derived cfDNA is mostly derived from hematopoietic cells [10], but in cancer patients a significant fraction can be derived from the tumor. In cancer patients, the proportion of tumor-derived cfDNA varies from less than 5 to more than 90% [9]. Overall cfDNA concentrations can vary widely between patients, with typical values spanning from 10 to 1200 ng/ml [9]. As cfDNA is often of very low abundance and highly fragmented, with a typical fragment size of ~180 bp [9], specialized protocols and assays are necessary for its analysis. Detection of HPV cfDNA in blood plasma can identify OPC patients with high sensitivity and specificity [11] and has been successfully used for diagnosis, prediction of

recurrence, and monitoring therapy response in OPC [12] [13] [14]. HPV cfDNA presence
after intended curative treatment is a highly specific predictor of recurrence, and recurrence
has been detected up to 5 months earlier by HPV cfDNA in comparison to standard imaging
techniques[15]. Therefore, HPV cfDNA is a promising candidate biomarker for a screening
approach due to being minimally invasive and a highly sensitive and specific biomarker for
HPV-driven malignancies [16]. Currently the standard method for analyzing cfDNA is digital
droplet PCR (ddPCR). The method relies on splitting the PCR into many thousand partitions,
usually by generating droplets in an emulsion (e.g. BioRad QX200), but nanoplate-based
approaches exist as well (e.g. QIAGEN QIAcuity), then referred to as digital PCR (dPCR). The
market for ddPCR devices is rapidly evolving, with new devices being capable of detecting
multiple targets at once. While the vast majority of HPV-OPC are caused by HPV16, there is
rising interest in detection of additional HPV types, especially in relatively high-incidence
countries [14]. In plasma samples at OPC diagnosis, the sensitivity of ddPCR has been
reported to range from 70% [17] to more than 98% [14]. ddPCR is more sensitive than qPCR
in HPV16-cfDNA detection from OPC and comes with lower costs than sequencing based
approaches, even though the latter have been reported to reach even higher sensitivity than
ddPCR [17]. Due to the fragmented nature of cfDNA in blood plasma, it is of high importance
for any PCR-based method to use very small amplicon sizes to maximize sensitivity of the
assay. Most studies have focused on application of the method for therapy surveillance or
diagnosis, where 3 ml of plasma or more are relatively easily available for analysis [13] [14]
[18]. To study the performance of HPV cfDNA as a predictive biomarker of HPV-OPC it is
necessary to analyze existing samples from biobanks or epidemiological cohorts, where
often only small amounts of plasma are available.

In this setting, antibodies against HPV16 oncoproteins, especially E6, have been shown to be
highly specific and sensitive predictive biomarkers of OPC [19]. Seroconversion has been
observed to occur up to 10 or more years before diagnosis [20]. HPV16 oncoprotein
antibody patterns have been successfully used to identify individuals at risk for development
of HPV-OPC in a prospective manner before onset of symptoms [21] [22]. However, due to
the long lead time, repeated in-depth exams by otorhinolaryngologists are necessary over
time for early detection of OPC, putting a considerable burden on both the patients and the
healthcare system. Therefore, a minimally invasive biomarker for HPV-OPC is necessary in
order to correctly identify people at imminent risk of developing HPV-OPC.

The aim of this study was to establish an optimized protocol for the purification and
quantification of HPV-cfDNA from small volumes of blood plasma (i.e. below 1 ml). While
nucleic acid purification efficiency is usually not a key determinant of cfDNA detection when

routine amounts of blood plasma (typically 3-4 ml) are available, it becomes more important

when only limited amounts of plasma are available. Blood plasma samples from volunteers

were used to compare cfDNA purification methods. On two different digital PCR platforms

(BioRad QX200 and QIAcuity One) an assay targeting HPV16, HPV33 and the human

reference gene beta-globin (BG) was developed to detect HPV-cfDNA. After determining

analytic sensitivity, DNA from cervical swab samples was analyzed to ensure HPV type

specificity of the assay. The 89 available liquid biosy samples from OPC patients were split

into a training set of 24 samples and a validation set of 65 samples. The training set was

used to optimize the dPCR assay, and final sensitivity and specificity were determined in the

validation set.

148 2. Material and Methods

149 2.1. **OPC patient inclusion and testing**

Sodium citrate plasma samples from 86 OPC patients from Ulm University Hospital were

collected (tbl. 2.1. , Ethical approval 90/15, Ulm University Ethics Commission). Tumor HPV

status was determined by p16-IHC [4] and HPV DNA detection by GP5+/6+ PCR [23] and

subsequent sequencing of PCR products for HPV typing. OPC were classified as HPV-driven

by a pathologist if the tumor section was both HPV-DNA and p16-IHC positive. Tumors

which tested negative for either p16 or HPV-DNA (or both) were considered to be HPV-

negative. Three patients in the validation cohort had one blood sample taken at initial

diagnosis and one at recurrence with distant metastasis. Inclusion criteria for the study were

the diagnosis of a tumor in the oropharynx with complete tumor HPV-DNA and p16-IHC

data. Samples were assigned to the training and validation sets by the treating physician

who was not directly involved in the experiments to achieve balanced distributions of HPV-

driven and HPV-negative tumors in both sets. The two sets did not differ significantly when

examining tumor stage, nodal stage and other characteristics (tbl. 2.1). dPCR experiments

were conducted by personnel blinded to tumor HPV status. Available plasma volumes from

24 OPC patients (12 HPV16-driven, 2 HPV33-driven, 10 HPV-negative) in the training set

ranged from 0.38 to 2.9 ml (mean volume 1.14 ml). The samples were collected between

2013 and 2020 (mean storage time since blood draw 5.5 years). In the validation set of 65

plasma samples from 62 HPV-OPC patients (33 HPV16-driven, 2 HPV58-driven, 1 HPV33-

driven, 26 HPV-negative) available plasma volumes varied between 0.37 and 3 ml (mean

volume 1.01 ml).

Table 2.1: Patient characteristics of the training and validation sets.

Characteristic	Training set (n=24)	Validation set (n=62)[1]	p-value
HPV type (DNA)			0.38[2]
16	12 (50%)	33 (53%)	
33	2 (8.3%)	1 (1.6%)	
58	0 (0%)	2 (3.2%)	
HPV-negative[3]	10 (42%)	26 (42%)	
p16-IHC			0.89[2]
1	14 (58%)	39 (63%)	
0	10 (42%)	23 (37%)	
Age at diagnosis[4]	58 (54, 63)	61 (56, 67)[5]	0.13[6]
Sex			0.24[2]
male	21 (88%)	45 (73%)	
female	3 (13%)	17 (27%)	
OPC subsite			0.24[2]
tonsil	14 (58%)	48 (77%)	
base of tongue	9 (38%)	11 (18%)	
soft palate	1 (4.2%)	2 (3.2%)	
lateral pharyngeal wall	0 (0%)	1 (1.6%)	
T stage			0.81[2]
T1/2	13 (54%)	32 (52%)	
T3/4	11 (46%)	29 (47%)	
Unknown	0 (0%)	1 (1.6%)	
N stage			0.56[2]
N0/1	15 (63%)	44 (71%)	
N2/3	9 (38%)	17 (27%)	

Unknown	0 (0%)	1 (1.6%)	
Stage[7]			0.77[2]
Stage 1/2	14 (58%)	39 (63%)	
Stage 3/4ab	10 (42%)	21 (34%)	
Stage 4/4c	0 (0%)	1 (1.6%)	
Unknown	0 (0%)	1 (1.6%)	

172 N (%), [1]For 3 patients from the validation set each 2 samples were available, [2]Pearson's Chi-
173 squared test, [3]high-risk HPV negative, [4]Median (IQR), [5]Age missing for one patient,[6]Wilcoxon
174 rank sum test, [7]AJCC TNM8

2.2. Healthy donor plasma sample collection

Healthy volunteers were recruited in Heidelberg, Germany, and both EDTA and sodium
citrate blood plasma samples were collected by medically trained personnel at the German
Cancer Research Center (DKFZ) (Ethical approval S-031/2022, University Heidelberg Ethics
Commission). Anonymized blood samples were processed within 1 h after collection by
centrifugation at 600 x g for 10 minutes. The plasma phase was separated and centrifuged
again at 1200 x g for 10 minutes. The resulting plasma was split into 1 ml aliquots and stored
at -80°C. For each experiment, a minimum of 5 plasma sample aliquots were pooled and
thoroughly mixed before proceeding.

2.3. cfDNA isolation and purification efficiency assessment

Before nucleic acid isolation, plasma samples were equilibrated to room temperature and
centrifuged at 3000 x g for 5 minutes. Automated cfDNA purification was performed using
the *DNA and Viral NA Large Volume* kit for the MagNA Pure 96 (Roche Diagnostics,
Mannheim, Germany). cfDNA was purified from EDTA plasma using the *cfNA ss 2000* or *cfNA
ss 4000* protocol, depending on the available plasma volume, and the *Viral NA Universal 500*
or *Viral NA Universal 1000* protocol for sodium citrate plasma, as recommended by the
manufacturer. The sample volume was assessed based on the sample weight and then
adjusted to the necessary input volume for each protocol by adding PBS (e.g. 1500 μl plasma
plus 500 μl of PBS for the *cfNA ss 2000* protocol), as recommended by the manufacturer.
Purified DNA was eluted in 50 μl elution buffer.

The isolation efficiency of the MagNA Pure 96 protocols was compared to the *QIAamp*

ccfDNA/RNA kit (QIAGEN, Hilden, Germany) to identify the ideal protocol for cfDNA

isolation. Isolation by the *QIAamp* kit was conducted according to the manufacturer's

instructions and 20 µl of RNAse-free water was used in the final elution step. To identify the

optimal DNA purification method, HPV16 DNA was spiked into blood plasma from healthy

volunteers (spike-in experiments). 10^4 copies of a 104 bp HPV16 E6 DNA fragment

quantified by Agilent Bioanalyzer (Agilent High Sensitivity DNA Kit) were added to pooled

plasma samples from healthy volunteers immediately prior to cfDNA isolation. The pooled

plasma samples were then thoroughly mixed and split into several aliquots to conduct

cfDNA isolation and quantification in multiple replicates across the different kits. For each

replicate the same volume of plasma was used, and adjusted with PBS to the minimum

input volume of the kit, as described above. As a reference, the original material used for

spike-in was separately quantified in each QIAcuity dPCR run. Isolation efficiency was

calculated as the number of copies of spike-in DNA detected after isolation divided by the

number of copies detected in the original material used for spike-in.

2.4. Testing HPV type specificity on cervical swab samples

Cervical swabs were collected at a colposcopy clinic in Berlin (MVZ) and stored in PreservCyt

buffer at 4°C [24]. Samples used were HPV negative (n=21) or positive for HPV16 (n=20),

HPV33 (n=11), both HPV16 and HPV 33 (n=2), HPV58 (n=8), HPV31 (n=19), HPV35 (n=2), or

HPV52 (n=9) as determined by multiplex papillomavirus genotyping (MPG) assay [25].

Samples were vortexed vigorously for 20 seconds and 250 µl were used for DNA

purification. PBS was used to adjust the volume to the required input volume of the kit

used. DNA was isolated using the MagNA Pure 96 *Pathogen Universal 500* protocol, using 50

µl of elution buffer. 1 µl of the eluate was used for PCR.

2.5. DNA quantification by dPCR and ddPCR

Isolated DNA was analyzed using both the QX200 ddPCR (BioRad) and the QIAcuity dPCR

(QIAGEN). Both digital PCR assays quantified HPV16 E6 and the human reference gene beta-

globin (BG) using specific primers and probes (duplex assay) [26]. On the QIAcuity One,

which comes with multiple fluorescence channels to quantify up to five different targets,

the assay was complemented by primer-probe sets specific for HPV33 E6 (forward primer:

CCAAGCATTGGAGACAACTATAC, probe: TEX-CAACATTGAACTACAGTGCGTGGAATG-BHQ2,

reverse primer: AATCATATACCTCAGAT CGTTGC) and HPV16 E7 (forward primer:

AAGCAGAACCGGACAGAG, probe: HEX-TGTTGCAAGTGTGACTCTACGCTTCG-BHQ1, reverse

primer: TCTACGTGTGTGCTTTGTACG), thus targeting four different targets (four-plex assay).

These primers were designed by identifying the most conserved regions in 29 HPV33 E6 and

638 HPV16 E7 sequences available on NCBI GenBank. Criteria for primer and probe design

included suitable melting temperature (ca. 60°C) as calculated by the nearest-neighbour

method according to Allawi et al. (1998) [27], a maximum GC content of 70%, and minimal

self- and cross-complementarity to prevent the formation of primer-dimers. ddPCR on the

QX200 system was conducted in 40 cycles of 94°C denaturation for 30 seconds and

annealing and elongation at 58°C for 1 minute. dPCR on the QIAcuity One was conducted in

40 cycles of 95°C denaturation for 10 seconds and 60°C annealing and elongation for 30

seconds. For the comparison of the two PCR platforms using the training set an input of 10

µl of cfDNA was added per reaction, while in the validation set, where dPCR was run on

QIAcuity alone, the volume was 20 µl per reaction. As positive controls, and for dilution

series, plasmids carrying the full HPV16 and HPV33 genomes and BG were used [28,29]. The

positive control contained 10^4 copies of HPV16, HPV33 and human BG. Dilution series

spanned from 1.1×10^5 to 1.9 copies of those templates in 3-fold dilution steps for

determining the analytic sensitivity of the assay.

244   2.6. **Statistical analysis**

Initial analysis of the QIAcuity data was conducted using the QIAcuity Software Suite V 2.2.

Results exported from the software were further analyzed in R version 4.3.1 [30]. Packages

from the tidyverse family of R-packages [31], epiR [32] and caret [33] were used. In the

assessment of analytic sensitivity, the limit of detection (LoD) was defined as the lowest

input copy number that yielded a positive result in both duplicates. In the cervix, HPV

infection is common, but extremely low viral loads are most likely clinically irrelevant and

may not have been detected by reference tests. Therefore, in cervical swab samples all

samples were only considered HPV-positive if a minimum of 3 partitions was positive for any

target. As even in blood plasma samples from patients with HPV-driven malignancies low

amounts of HPV DNA are expected, in the training set of plasma samples any sample with

any positive partition was classified as HPV-positive. Based on the results of the training set,

cfDNA samples were only classified as HPV-positive when both replicates were HPV cfDNA-

positive in the validation set of plasma samples to ensure sufficient specificity of the assay.

Clinical sensitivity was defined as the number of samples from patients with HPV16 or

HPV33-driven tumors that tested positive for HPV cfDNA divided by the number of all

patients with HPV16 or HPV33-driven tumors. Clinical specificity was defined as the number

of samples from HPV16 and HPV33-negative patients which tested negative for HPV cfDNA

divided by the total number of HPV16 and HPV33-negative patients. For sensitivity and

specificity the Clopper-Pearson confidence interval (CI) was computed.

3. Results

3.1. **Comparison of PCR platforms**

3.1.1. **Analytic sensitivity and HPV type specificity**

Analytic sensitivity of QX200 ddPCR and QIAcuity dPCR were compared by applying a three-fold serial dilution of the corresponding template DNA in duplicates. Since the QX200 ddPCR assay quantifies BG and HPV16 E6 only, these two targets were used for a direct assay comparison. The QX200 ddPCR had a LoD of 17 copies for both HPV16 E6 and BG (fig. 3.1A). The QIAcuity dPCR (fig. 3.1A and B) had a lower LoD of 6 copies for HPV16 E6, HPV16 E7 and BG, and a LoD of 17 copies for HPV33 E6.

To assess the specificity of the assay on both PCR platforms, DNA from 92 cervical swab samples with known HPV infection status was tested. Any sample with 3 or more positive partitions was counted as positive for the given target. In the QX200 ddPCR, HPV16 E6 was 100% specific (n=77/77, fig. 3.1C). Sensitivity was 95.5% (n=21/22 detected), based on one false negative sample that was defined as HPV16 and HPV33 positive by the reference method and yielded less than 3 HPV16 positive partitions. In QIAcuity dPCR, HPV16 E6 was 100% type-specific and 100% sensitive for both HPV16 single infections (n=20/20) and co-infections with HPV33 (n=2/2, fig. 3.1C). However, 12 non-HPV16 cases (out of 77) showed one to two partitions positive for HPV16 E6. HPV16 E6 quantification by the two methods was highly correlated (Pearson's r = 0.97) and virtually identical (slope of regression model = 0.93).

In QIAcuity dPCR, HPV16 E7 and HPV33 E6 were quantified in the same reaction. HPV16 E7 had a sensitivity of 100% for HPV16 single infections (n=20) and double infections with other HPV types (n=2) (fig. 3.1D). HPV33 E6 had a sensitivity of 100% for HPV 33 single infections (n=11) and double infections (n=2). While specificity for HPV16 E7 was 100%, one sample with an HPV16 infection was tested positive for HPV33, however with only 7 positive partitions, which is the lowest number detected in any sample. Consequently, the specificity of the HPV33 E6 assay was 98.8% (n=78/79). Overall, no HPV DNA was detected in any sample that was previously tested negative for HPV DNA or for HPV types other than HPV16 and HPV33.

Figure 3.1: (A) Quantification of a dilution series of HPV16 E6 and beta-globin (BG) template DNA on a QX200 ddPCR system (x-axis) compared to QIAcuity dPCR (y-axis). Values shown are the minimum of duplicates. **(B)** Quantification of a dilution series of HPV16 and HPV33 DNA on QIAcuity dPCR by primers targeting HPV16 E7 and HPV33 E6. Values shown are the minimum of duplicates, the shaded area indicates the standard deviation. **(C)** Copy numbers of HPV16 E6 detected by QX200 ddPCR (y-axis) and QIAcuity dPCR (x-axis) in cervical swab samples with known HPV status. The red lines indicate the cut-off of 3 copies to distinguish positive and negative samples. The black line is a regression line fitted to the data (y = 0.11+0.93x, r=0.97). Not all colors visible due to data overlay at zero copies. **(D)** Copy numbers of HPV16 E7 and HPV33 E6 detected by QIAcuity dPCR in cervix samples with known HPV status. The red line indicates the cut-off of 3 copies to distinguish positive and negative samples.

3.1.2. cfDNA analysis in a training set of 24 OPC patients

24 plasma samples from OPC patients (12 HPV16-driven, 2 HPV33-driven, 10 HPV-negative) were analyzed to compare the QX200 ddPCR targeting HPV16 E6 and BG, and the QIAcuity dPCR targeting HPV16 E6 and BG, and HPV16 E7 and HPV33 E6 in addition. All samples were tested in duplicates.

When tested in ddPCR on the QX200 system, all samples were positive for BG in both replicates with a mean of 6,022 copies/ml detected (range 371 – 30,678 copies/ml), indicating sufficient DNA amount and quality. In total, 13 out of 24 samples had any positive

droplets for HPV16 E6 (range 3.33 – 8,750 copies/ml, fig. 3.2A). Three of these were false

positive with low HPV16 E6 copies (3.33 – 11 copies/ml), yielding a specificity of 75% (9/12,

95% CI: 43 – 95%). Two of these were positive for HPV33, but not HPV16, in tumor tissue.

The assay had a sensitivity of 83% for HPV16-driven OPC cases (10/12, 95% CI: 52 – 98%). If

only samples that were positive for HPV16 in both replicates were counted as HPV16

positive, the sensitivity decreased to 58% (7/12, 95% CI: 28 – 62%) and specificity increased

to 92% (11/12, 95% CI: 62 - 100%) (fig. 3.2B). The lowest concentration that was

reproducibly tested positive was 11 copies/ml.

When the assay was run with the extended dPCR target panel on the QIAcuity One, a mean

concentration of 6,235 copies/ml of BG per ml was detected (201 – 55,220 copies/ml),

indicating sufficient DNA amount and quality in all samples. The assay had an overall

sensitivity of 71% (10/14, 95% CI: 42 - 92%) for HPV16 (E6 and/or E7) and HPV33, and a

specificity of 100% (10/10, 95% CI: 69 - 100%) (fig. 3.2C). HPV33 E6 had a sensitivity of 100%

(2/2, 95% CI: 16 - 100%) for HPV33-driven OPC cases and a specificity of 100% (22/22, 95%

CI: 91 – 100%). HPV16 E6 had a sensitivity of 50% (6/12, 95% CI: 21 – 79%) and HPV16 E7 of

66% (8/12, 95% CI: 35 – 90%) for HPV16-driven OPC cases. The positive samples for each of

the targets contained a mean of 3,482 copies of HPV16 E6 (range 21.2 – 22,780 copies/ml),

3,431 copies of HPV16 E7 (range 10.6 – 28,880 copies/ml) and 42.7 copies of HPV33 E6

(range 10.6 – 74.8 copies/ml). Six samples were positive for HPV16 E6 and E7 and two

additional samples were positive for HPV16 E7 only, indicating a better performance of the

HPV16 E7 assay. The quantification of HPV16 E6 and E7 was highly correlated (Pearson's r >

0.99, fig. 3.3A). Cohen's kappa was 0.476 for HPV16 E6, 0.645 for HPV16 E7 and 1.0 for

HPV33 E6, indicating moderate to perfect agreement with tumor HPV status. There was no

correlation of HPV16 E7 copy numbers with BG copy numbers (Pearson's r = 0.01, fig. 3.3B).

There was a weak correlation between the number of BG copies detected and the plasma

volume (Pearson's r = 0.221, fig. 3.3C).

Both HPV16 assays had a specificity of 92% due to one false positive result in a sample from

an HPV33-driven OPC patient. One plasma sample from an HPV33-driven OPC case

reproducibly tested positive for HPV16 E6 (2/2 replicates on QIAcuity, 2/2 replicates on

QX200) and HPV16 E7 (2/2 replicates on QIAcuity) in addition to HPV33 E6 (2/2 replicates),

likely indicating that an HPV16 infection was missed in the tumor tissue.

Figure 3.2: dPCR results of 24 patients from the training set (10 HPV-negative, 12 HPV16+, 2 HPV33+). Samples categorized as positive or negative depending on the HPV-type targeted by each experiment. (A) Copy number of HPV16 E6 cfDNA by QX200 ddPCR, showing the mean value of the replicates. (B) Copy number of HPV16 E6 cfDNA by QX200 ddPCR, showing the minimum value of the replicates. (C) Copy number of HPV16 E6, HPV16 E7 and HPV33 E6 cfDNA by QIAcuity dPCR, showing the minimum value of the replicates.

Figure 3.3: Number of copies of different target DNA detected in plasma samples from 24 OPC patients by QIAcuity dPCR. Each point represents one of two replicates from a sample. (A) Comparison of HPV16 E6 and HPV16 E7 copies detected in each sample. (B) Comparison of copy number of HPV16 E7 and BG copies in each sample. (C) Comparison of number of copies of BG detected and the input blood plasma volume.

3.2. **Optimization of cfDNA purification**

In order to optimally detect low concentrations of cfDNA in small volumes of less than 1 ml of blood plasma, the performance of different nucleic acid purification methods was analyzed. The automated *cfNA ss 2000* protocol for the MagNA Pure 96 was compared with the manual *QIAamp ccfDNA/RNA* kit using plasma from healthy volunteers with spiked-in HPV16 plasmid DNA. To ensure comparability, one plasma pool was split into multiple aliquots and tested on both platforms. Based on the quantification of spiked-in HPV16 DNA by QIAcuity dPCR, mean isolation efficiency was higher using the cfNA-protocol for the MagNA Pure 96 *cfNA ss 2000* (51%) compared to *QIAamp ccfDNA/RNA* kit (23%) (fig. 3.4A). Similarly, a higher number of BG copies from the native cfDNA were detected in the MagNA Pure 96 *cfNA ss 2000* extract (median 1,499 copies/ml) compared to the *QIAamp ccfDNA/RNA* extract (median 372 copies) (fig. 3.4B). When using the MagNA Pure 96 *cfNA ss 2000* protocol for isolating HPV DNA spiked into healthy donor EDTA plasma, as few as 10 copies of HPV DNA were detected in 8 of 8 replicates (100% sensitivity) in the subsequent QIAcuity dPCR, while with 5 copies the sensitivity was 75% (6/8 replicates). When cfDNA was isolated from sodium citrate plasma samples from healthy volunteers, the MagNA Pure 96 *cfNA ss 2000* protocol yielded fewer copies of BG per ml of plasma in 3 out of 4 samples than the *Viral NA Universal 500* protocol, despite using the same input volume in both protocols (fig. 3.4C). Consequently, the latter protocol was used for the sodium citrate plasma samples in the validation experiment.

Figure 3.4: Performance of nucleic acid isolation from blood plasma. (A) Recovery rate of a
104 bp HPV16 fragment from EDTA plasma by MagNA Pure 96 *cfNA ss 2000 protocol* **(MP96)**
or *QIAamp ccfDNA/RNA kit* **(QIAamp). The red triangle indicates the position of the group**
mean. (B) Number of copies of native BG cfDNA isolated from aliquots of one EDTA plasma
pool by MP96 and QIAamp. (C) Comparison of MagNA Pure 96 *cfNA ss 2000 protocol* **and the**
Viral NA Universal 500 protocol **for sodium citrate plasma.**

3.3. **Effect of sample volume on quantification**

To gain insight about the effect of the sample volume on sensitivity, aliquots of 500 and

1000 µl were analyzed from 30 plasma samples from OPC patients (15 HPV16+, 2 HPV58+,

13 HPV-negative). The samples were analyzed in duplicates by QIAcuity dPCR.

All samples in both of the two groups (500 µl vs. 1000 µl) had sufficient human BG DNA.

When 1000 µl of plasma were used for cfDNA isolation, the HPV16 E7 dPCR had a sensitivity

of 80% for HPV16-driven tumors (n=12/15), while HPV16 E6 had a sensitivity of 73%

(n=11/15) (fig. 3.5). When 500 µl of sample was analyzed, the assay had a sensitivity of 73%

(n=11/15) for both HPV16 E6 and E7. In total only one HPV-driven OPC case was not

detected due to decreased input plasma volume. There were two false positive samples,

leading to a specificity of the assay of 87% (n=13/15). In one HPV58+ OPC plasma sample

very low amounts (2.5 copies/ml) of HPV16 E7-cfDNA only were detected in 500 µl extract

only. The other false positive plasma sample was from an OPC case where the

corresponding tumor tissue was HPV DNA-negative but p16-positive. This sample tested

concordantly positive for both HPV16 E6 and E7 cfDNA in both plasma aliquots of 500 and

1000 µl, likely indicating a missed HPV16 infection in the tumor tissue. Overall, the

quantification of cfDNA copies per ml was very consistent between the two sample volumes

for HPV16 E6 and E7 (r>=0.99), and was comparable for human BG (r=0.86).

Figure 3.5: QIAcuity dPCR result of 30 OPC patient plasma samples (13 negative, 2 HPV58+, 15 HPV16+), comparing the concentration of each target (in copies/ml plasma) between cfDNA isolated from 500 µl (y-axis) and 1000 µl (x-axis) of plasma. (A) HPV16 E7, (B) HPV16 E6, (C) BG.

3.4. Validation of final protocol in plasma samples from OPC patients

For the final assessment of clinical sensitivity and specificity, a total of 65 plasma samples from OPC patients (34 HPV16+, 1 HPV33+, 2 HPV58+, 28 HPV negative) were analyzed, using the results from 1000 µl plasma volume where available. In the following analysis, HPV58-driven OPC cases were considered HPV-negative as the assay was not targeted to detect this HPV type. cfDNA was purified from plasma samples by MagNA Pure 96 *Viral NA Universal* protocol and applied in duplicates to QIAcuity dPCR. Only samples that tested reproducibly positive for a given target were considered positive for this target, based on results from the training set. Sample volumes analyzed for each sample ranged from 370 to 1000 µl (mean of 824 µl). The samples contained a median of 684 copies/ml of BG (range 223 – 80,982 copies/ml).

Samples diagnosed as HPV16 or HPV33-driven by pathology were classified correctly with a
sensitivity of 80% (28/35, 95% CI: 63 – 92%, tbl. 3.1) and with a specificity of 96.7% (29/30,
95% CI: 83 – 100%). The test had a Cohen's kappa of 0.756, indicating substantial agreement
with the tumor HPV status. In samples with 350 – 500 µl of plasma available, the sensitivity
of the assay was lower with 73.3% (11/15, 95% CI: 45 – 92%), while in samples with 750 –
1000 µl of plasma the sensitivity was 85% (17/20, 95% CI: 62 - 97%). A moderate correlation
between N-stage and HPV16 E7 copy numbers detected in plasma samples from HPV16-
driven OPCs was observed (r= 0.289), while there was a weak correlation with T-stage (r=
0.128). There was no correlation between BG copy numbers detected and the sensitivity of
the assay, but 5 out of 5 cases with more than 10,000 copies of beta-globin were HPV-
driven. The age of the sample had no effect on the number of copies of BG detected in the
plasma samples (r= -0.076).

Table 3.1: Performance of QIAcuity dPCR of plasma cfDNA compared to tumor HPV status.

cfDNA[1]	Tumor HPV status (HPV DNA + p16-IHC)	
	HPV16 +	**HPV16 -**
HPV16 E7+	27	2
HPV16 E7-	7	29
	HPV16 +	**HPV16 -**
HPV16 E6+	22	2
HPV16 E6-	12	29
	HPV33 +	**HPV33 -**
HPV33 E6+	1	0
HPV33 E6-	0	64
cfDNA[1]	**HPV16/33 +**	**HPV16/33 -**
HPV+[2]	28	1
HPV-[2]	7	29
Sensitivity	0.800 (95% CI: 0.63 - 0.92)	
Specificity	0.967 (95% CI: 0.83 - 1.00)	
Kappa	0.756 (95% CI: 0.68 - 0.84)	

433   [1] HPV detected in plasma by QIAcuity dPCR, [2] HPV+/- summarizes the results of HPV16 E7,

434   HPV16 E6 and HPV33 E6 dPCR; the overall result was positive if any of the three targets was

435   detected in both duplicates for a sample.

436   4. Discussion

Early detection of OPC holds the potential to improve patient's quality of life due to early

therapeutic intervention requiring less intensive therapy. For this purpose, novel diagnostic

molecular biomarkers are needed using minimally invasive protocols. HPV cfDNA is a

promising candidate that is successfully being used in therapy surveillance of HPV-driven

OPC already. To evaluate this biomarker for early diagnosis a highly sensitive and specific

assay is needed that can also be successfully applied to archived material, where usually

only small amounts of plasma are available. Here, we describe a digital PCR assay targeting

HPV16 and HPV33.

To optimize the assay at every step from DNA isolation from plasma to DNA detection and

quantification, multiple comparisons of methods were conducted. Due to the superior

cfDNA isolation efficiency of the MagNA Pure 96 over the QIAamp kit, the MagNA Pure 96

was used in the final validation set of samples. While the QX200 and QIAcuity showed

comparable analytical and clinical sensitivity, the QIAcuity offers higher multiplexing

capacity, which enables the targeting of multiple HPV types at once. In addition, the effect

of the sample volume on the sensitivity was evaluated. Our results suggest that it is feasible

to use lower input volumes than seen in most studies, as using only up to 1 ml of plasma in

the validation experiment yielded a sensitivity of 80%, which is comparable to other studies

which achieved 70 – 96% sensitivity working with 2 – 4 ml of plasma per sample [13] [15]

[18] [17]. Since even in samples with 500 µl or less plasma available the sensitivity was still

73.3%, the assay is suitable for use in archived samples from large collections in biobanks,

where usually only small volumes are available.

The increase in sensitivity from the training set (71%) to the validation set (80%) could be

explained by an increased PCR input volume from 10 to 20 µl, due to increased sample

volume requirements in the training set for the comparison of two different dPCR methods,

and the use of an optimized cfDNA purification method in the validation set. The

unexpectedly low cfDNA yield in samples with high input volumes prompted a more in-

depth comparison of different cfDNA isolation protocols for these samples. This led to the

conclusion that the *Viral NA Universal* protocols give a higher yield in these samples than

the cfDNA protocols, so that the protocol used for cfDNA isolation was changed in the

validation set.

The specificity of the QIAcuity dPCR in the final validation set was 96.6%. The one
reproducibly false HPV16 E6 and E7 cfDNA positive plasma sample by dPCR was from a
patient with a tumor that was tested HPV DNA-negative and p16-positive by a pathologist.
The same plasma sample has been previously tested positive for antibodies against multiple
HPV16 antigens using multiplex serology, which is an assay that has a very high specificity
[34] [35]. Therefore it seems likely that the HPV DNA in the tumor tissue has been missed by
the reference assay, and it could be reasonably assumed that the tumor was actually HPV-
driven, which would set the actual specificity of the assay to 100%.

In the training set and the experiment for the direct comparison of cfDNA isolated from
different volumes, three additional false positive cases emerged. In contrast to the HPV DNA
result of corresponding tumor tissue samples, additional HPV16 DNA was detected in three
plasma samples from HPV33 or HPV58-driven OPC patients. This could be explained by
either lack of type-specificity of the assay when applied to cfDNA, which seems unlikely as
there was no cross-reactivity in cervical swab samples positive for any of these HPV-types,
or previously undetected co-infections driving the cancer in these cases due to sensitivity
limitations of the reference test. In cervical swabs within this study there were multiple
cases of co-infection with these HPV types, which have also been frequently observed in
other studies [36], although whether these findings are applicable to the oropharynx
requires further investigation.

Although HPV16 is the most common HPV type among HPV-driven OPC, one limitation of
the assay is the small number of HPV types covered. In our study, HPV58 was present almost
as frequently as HPV33. However, only HPV33 was included in the assay due to limited
multiplexing spectrum of the dPCR. Since all HPV16 E6 positive sample were also HPV16 E7
positive, in future studies HPV16 E6 could be replaced by primers and probes detecting
other HPV types.

Since therapy surveillance is a well-established use for HPV cfDNA detection, a more
interesting question to answer would be the kinetics of HPV cfDNA before diagnosis of HPV-
driven cancer. The possibility of using lower input volumes may open up new sample
sources that would not be able to provide the volumes usually used for cfDNA isolation. The
assay presented in this study is sensitive and specific even for these smaller input volumes
and thus could help exploring the utility of HPV cfDNA in early detection of HPV-driven
cancers, which could be feasible due to only requiring minimally invasive sampling.

5. Conclusions

Briefly, we established a novel dPCR detecting HPV16 E6 and E7, HPV33 E6 and the internal BG control on the QIAcuity in archived, low volume plasma samples after using automated DNA extraction with the MagNA Pure 96. The dPCR was shown to detect sensitively and specifically HPV16 and HPV33. Follow-up studies in larger cohorts are required to explore the use of HPV cfDNA in early detection of HPV-driven OPC.

6. Funding sources

This study was funded by intramural DKFZ funding.

References

[1]   Szymonowicz KA, Chen J. Biological and clinical aspects of HPV-related cancers. Cancer Biol Med 2020;17:864–78. https://doi.org/10.20892/j.issn.2095-3941.2020.0370.

[2]   Pytynia KB, Dahlstrom KR, Sturgis EM. Epidemiology of HPV-associated oropharyngeal cancer. Oral Oncol 2014;50:380–6. https://doi.org/10.1016/j.oraloncology.2013.12.019.

[3]   Hong AM, Martin A, Armstrong BK, Lee CS, Jones D, Chatfield MD, et al. Human papillomavirus modifies the prognostic significance of t stage and possibly n stage in tonsillar cancer. Ann Oncol 2013;24:215–9. https://doi.org/10.1093/annonc/mds205.

[4]   Mahajan A. Practical issues in the application of p16 immunohistochemistry in diagnostic pathology. Hum Pathol 2016;51:64–74. https://doi.org/10.1016/j.humpath.2015.12.021.

[5]   You EL, Henry M, Zeitouni AG. Human papillomavirus-associated oropharyngeal cancer: Review of current evidence and management. Curr Oncol 2019;26:119–23. https://doi.org/10.3747/co.26.4819.

[6]   Pinkiewicz M, Dorobisz K, Zatonski T. Human papillomavirus-associated head and neck cancers. Where are we now? A systematic review. Cancer Manag Res 2022;14:3313–24. https://doi.org/10.2147/CMAR.S379173.

[7]   Hirth JM, Chang M, Resto VA, Group HPVS. Prevalence of oral human papillomavirus by vaccination status among young adults (18-30years old). Vaccine 2017;35:3446–51. https://doi.org/10.1016/j.vaccine.2017.05.025.

[8] Damgacioglu H, Sonawane K, Chhatwal J, Lairson DR, Clifford GM, Giuliano AR, et al.
Long-term impact of HPV vaccination and COVID-19 pandemic on oropharyngeal
cancer incidence and burden among men in the USA: A modeling study. Lancet Reg
Health Am 2022;8:100143. https://doi.org/10.1016/j.lana.2021.100143.

[9] Jahr S, Hentze H, Englisch S, Hardt D, Fackelmayer FO, Hesch RD, et al. DNA
fragments in the blood plasma of cancer patients: Quantitations and evidence for
their origin from apoptotic and necrotic cells. Cancer Res 2001;61:1659–65.

[10] Lui YY, Chik KW, Chiu RW, Ho CY, Lam CW, Lo YM. Predominant hematopoietic origin
of cell-free DNA in plasma and serum after sex-mismatched bone marrow
transplantation. Clin Chem 2002;48:421–7.

[11] Nguyen B, Meehan K, Pereira MR, Mirzai B, Lim SH, Leslie C, et al. A comparative
study of extracellular vesicle-associated and cell-free DNA and RNA for HPV
detection in oropharyngeal squamous cell carcinoma. Sci Rep 2020;10:6083.
https://doi.org/10.1038/s41598-020-63180-8.

[12] Cao Y, Haring CT, Brummel C, Bhambhani C, Aryal M, Lee C, et al. Early HPV ctDNA
kinetics and imaging biomarkers predict therapeutic response in p16+ oropharyngeal
squamous cell carcinoma. Clin Cancer Res 2022;28:350–9.
https://doi.org/10.1158/1078-0432.CCR-21-2338.

[13] Chera BS, Kumar S, Beaty BT, Marron D, Jefferys S, Green R, et al. Rapid clearance
profile of plasma circulating tumor HPV type 16 DNA during chemoradiotherapy
correlates with disease control in HPV-associated oropharyngeal cancer. Clin Cancer
Res 2019;25:4682–90. https://doi.org/10.1158/1078-0432.CCR-19-0211.

[14] Siravegna G, O'Boyle CJ, Varmeh S, Queenan N, Michel A, Stein J, et al. Cell-free HPV
DNA provides an accurate and rapid diagnosis of HPV-associated head and neck
cancer. Clin Cancer Res 2022;28:719–27. https://doi.org/10.1158/1078-0432.CCR-
21-3151.

[15] Haring CT, Bhambhani C, Brummel C, Jewell B, Bellile E, Heft Neal ME, et al. Human
papilloma virus circulating tumor DNA assay predicts treatment response in
recurrent/metastatic head and neck squamous cell carcinoma. Oncotarget
2021;12:1214–29. https://doi.org/10.18632/oncotarget.27992.

[16] Tewari SR, D'Souza G, Troy T, Wright H, Struijk L, Waterboer T, et al. Association of
plasma circulating tumor HPV DNA with HPV-related oropharynx cancer. JAMA

Otolaryngol Head Neck Surg 2022;148:488–9.

https://doi.org/10.1001/jamaoto.2022.0159.

[17]   Mattox AK, D'Souza G, Khan Z, Allen H, Henson S, Seiwert TY, et al. Comparison of

next generation sequencing, droplet digital PCR, and quantitative real-time PCR for

the earlier detection and quantification of HPV in HPV-positive oropharyngeal

cancer. Oral Oncol 2022;128:105805.

https://doi.org/10.1016/j.oraloncology.2022.105805.

[18]   Damerla RR, Lee NY, You D, Soni R, Shah R, Reyngold M, et al. Detection of early

human papillomavirus-associated cancers by liquid biopsy. JCO Precis Oncol 2019;3.

https://doi.org/10.1200/PO.18.00276.

[19]   Holzinger D, Wichmann G, Baboci L, Michel A, Hofler D, Wiesenfarth M, et al.

Sensitivity and specificity of antibodies against HPV16 E6 and other early proteins for

the detection of HPV16-driven oropharyngeal squamous cell carcinoma. Int J Cancer

2017;140:2748–57. https://doi.org/10.1002/ijc.30697.

[20]   Kreimer AR, Ferreiro-Iglesias A, Nygard M, Bender N, Schroeder L, Hildesheim A, et

al. Timing of HPV16-E6 antibody seroconversion before OPSCC: Findings from the

HPVC3 consortium. Ann Oncol 2019;30:1335–43.

https://doi.org/10.1093/annonc/mdz138.

[21]   Waterboer T, Brenner N, Gallagher R, Hillman RJ, Jin F, Grulich A, et al. Early

detection of human papillomavirus-driven oropharyngeal cancer using serology from

the study of prevention of anal cancer. JAMA Oncol 2020;6:1806–8.

https://doi.org/10.1001/jamaoncol.2020.4527.

[22]   Busch CJ, Hoffmann AS, Viarisio D, Becker BT, Rieckmann T, Betz C, et al. Detection of

stage i HPV-driven oropharyngeal cancer in asymptomatic individuals in the hamburg

city health study using HPV16 E6 serology - a proof- of-concept study.

Eclinicalmedicine 2022;53. https://doi.org/ARTN

10165910.1016/j.eclinm.2022.101659.

[23]   Roda Husman AM de, Walboomers JM, Brule AJ van den, Meijer CJ, Snijders PJ. The

use of general primers GP5 and GP6 elongated at their 3' ends with adjacent highly

conserved sequences improves human papillomavirus detection by PCR. J Gen Virol

1995;76 (Pt 4):1057–62. https://doi.org/10.1099/0022-1317-76-4-1057.

[24]   Hofler D, Bohmer G, Wasielewski R von, Neumann H, Halec G, Holzinger D, et al.

HPV16 RNA patterns defined by novel high-throughput RT-qPCR as triage marker in

HPV-based cervical cancer precursor screening. Gynecologic Oncology
2015;138:676–82. https://doi.org/10.1016/j.ygyno.2015.06.039.

[25]   Schmitt M, Bravo IG, Snijders PJ, Gissmann L, Pawlita M, Waterboer T. Bead-based
multiplex genotyping of human papillomaviruses. J Clin Microbiol 2006;44:504–12.
https://doi.org/10.1128/JCM.44.2.504-512.2006.

[26]   Baboci L, Holzinger D, Boscolo-Rizzo P, Tirelli G, Spinato R, Lupato V, et al. Low
prevalence of HPV-driven head and neck squamous cell carcinoma in north-east
italy. Papillomavirus Res 2016;2:133–40. https://doi.org/10.1016/j.pvr.2016.07.002.

[27]   Allawi HT, SantaLucia Jr J. Thermodynamics of internal c.t mismatches in DNA.
Nucleic Acids Res 1998;26:2694–701. https://doi.org/10.1093/nar/26.11.2694.

[28]   Beaudenon S, Kremsdorf D, Croissant O, Jablonska S, Wain-Hobson S, Orth G. A novel
type of human papillomavirus associated with genital neoplasias. Nature
1986;321:246–9. https://doi.org/10.1038/321246a0.

[29]   Seedorf K, Krammer G, Durst M, Suhai S, Rowekamp WG. Human papillomavirus type
16 DNA sequence. Virology 1985;145:181–5. https://doi.org/10.1016/0042-
6822(85)90214-4.

[30]   R-Core-Team. R: A language and environment for statistical computing 2022.

[31]   Wickham H, Averick M, Bryan J, Chang W, D'Agostino McGowan L, Romain Françoi R,
et al. Welcome to the tidyverse. Journal of Open Source Software 2019;4:1686.
https://doi.org/10.21105/joss.01686.

[32]   Stevenson M, Sergeant E. epiR: Tools for the analysis of epidemiological data 2023.

[33]   Kuhn M. Building predictive models in r using the caret package. Journal of Statistical
Software 2008;28:1–26. https://doi.org/10.18637/jss.v028.i05.

[34]   Hibbert J, Halec G, Baaken D, Waterboer T, Brenner N. Sensitivity and specificity of
human papillomavirus (HPV) 16 early antigen serology for HPV-driven oropharyngeal
cancer: A systematic literature review and meta-analysis. Cancers (Basel) 2021;13.
https://doi.org/10.3390/cancers13123010.

[35]   Laban S, Gangkofner DS, Holzinger D, Schroeder L, Eichmuller SB, Zornig I, et al.
Antibody responses to cancer antigens identify patients with a poor prognosis
among HPV-positive and HPV-negative head and neck squamous cell carcinoma
patients. Clin Cancer Res 2019;25:7405–12. https://doi.org/10.1158/1078-0432.CCR-
19-1490.

[36]   Kim M, Park NJ, Jeong JY, Park JY. Multiple human papilloma virus (HPV) infections
are associated with HSIL and persistent HPV infection status in korean patients.
Viruses 2021;13. https://doi.org/10.3390/v13071342.

630 Appendix

631   To be written